GlassScriptPhysician profile
Jenny E Conrado
NPI 1043601453
$14,318.77
in general payments reported to CMS, 2019-2025
24 companies · $1,848 in 2025
The $1,848 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,991 · 2022: $3,153 · 2023: $2,399 · 2024: $2,928 · 2025: $1,848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,282 · Travel and Lodging: $803 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,281.58 |
| Travel and Lodging | $803.29 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,575.92 | 2021-2025 | Breztri, Airsupra, Tezspire |
| United Therapeutics Corporation | $2,344.53 | 2021-2025 | Orenitram, Tyvaso, Remodulin |
| Janssen Pharmaceuticals, INC | $1,935.95 | 2021-2023 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $1,805.84 | 2021-2025 | Uptravi, Opsumit |
| Inspire Medical Systems, INC. | $1,180.62 | 2024 | Inspire |
| Harmony Biosciences LLC | $942.84 | 2021-2024 | Wakix |
| Paratek Pharmaceuticals, INC. | $900.25 | 2021-2024 | Nuzyra |
| Jazz Pharmaceuticals INC. | $876.36 | 2021-2025 | |
| Glaxosmithkline, LLC. | $361.61 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Avadel Cns Pharmaceuticals, LLC | $233.66 | 2023-2025 | Lumryz |
| Axsome Therapeutics, INC. | $208.68 | 2022-2025 | Sunosi |
| Boston Scientific Corporation | $143.36 | 2025 | Intracept |
| Alnylam Pharmaceuticals INC. | $132.64 | 2022 | |
| Astellas Pharma US INC | $124.97 | 2024 | Veozah |
| Lilly USA, LLC | $124.96 | 2025 | Zepbound |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $111.11 | 2023 | Austedo |
| Merck Sharp & Dohme LLC | $84.86 | 2022-2025 | Winrevair |
| Bayer Healthcare Pharmaceuticals INC. | $74.78 | 2021 | |
| Resmed Corp | $39.29 | 2023 | |
| Merz North America, INC. | $37.43 | 2022 | |
| Nabriva Therapeutics, Plc | $25.28 | 2022 | |
| Genzyme Corporation | $22.30 | 2022 | |
| Esperion Therapeutics, INC. | $16.81 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.72 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenny Conrado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.